| 1 |
ClinicalTrials.gov (NCT04470726) Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma. U.S. National Institutes of Health.
|
| 2 |
Clinical pipeline report, company report or official report of AiViva BioPharma.
|
| 3 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
| 4 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 5 |
Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
|
| 6 |
National Cancer Institute Drug Dictionary (drug id 452042).
|
| 7 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 8 |
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
|
| 9 |
CA patent application no. 841416, Method of selecting therapeutic indications.
|
| 10 |
ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
|
|
|
|
|
|
|
